Figure 3: Activity of complex I and complex IV in control and psoriatic PBMC. PBMC from control and psoriatic patients were lysed and assayed spectrophotometrically as described in Materials and Methods for complex I and complex IV activity (A and B respectively). Where indicated in (A) PBMC were pre-treated with 100 μM isoproterenol plus 100 μM 3-isobutyl-1- methylxanthine (IMBX) for 15 min at 37°C in a CO2-incubator. The box-plots were constructed from the average values of 2-3 independent measurements for each control or psoriatic PBMC sample. White boxes, control; red boxes, psoriatic. Statistically significant differences are shown when P<0.05; NS, nonstatistically significant (i.e. P>0.05).